Journals / Ege Tıp Dergisi / 2017 / Cilt: 56 - Sayı: 4

Gestasyonel diabetes mellitusta osteopontin seviyeleri artmaz

Osteopontin levels do not increase in gestational diabetes mellitus

Pages
173–177
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In GDM the patients are experiencing rapid metabolic changes, so these metabolic changes may not affect the level of OPN.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Osteopontin (OPN) has recently been considered as marker of coronary artery disease.
📊
Key Findings & Data:The aim of this study is to evaluate OPN levels and investigate their correlation with the high sensitivity-CRP (hs-CRP) levels in patients with gestational diabetes mellitus (GDM), an increased state of insulin resistance.
💡
Conclusion & Impact:In GDM the patients are experiencing rapid metabolic changes, so these metabolic changes may not affect the level of OPN.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Osteopontin (OPN) has recently been considered as marker of coronary artery disease. The aim of this study is to evaluate OPN levels and investigate their correlation with the high sensitivity-CRP (hs-CRP) levels in patients with gestational diabetes mellitus (GDM), an increased state of insulin resistance. Materials and Methods: Fifty-four GDM patients and 40 healthy pregnant patients were included in this study. Biochemical tests for lipid profile, fasting blood glucose, oral glucose tolerance test, OPN, HOMA-IR and hs-CRP were done at 24th gestational week. Serum levels of OPN were measured by enzyme-linked immunosorbent assays (ELISAS), serum hs-CRP levels were measured by particle association turbidometric assay. Results: Gestational week, age, BMI of two groups were similar (p 0.05). The GDM group had significantly higher fasting, and post-load (1St and 2nd hour) blood glucose, HbA1c, fasting insulin and HOMA-IR levels than those of the healthy group. Except triglyceride levels, the lipid profiles of two groups were not significantly different. The GDM group had higher triglyceride levels than the control group (p 0.05). The hs-CRP levels were 0.94:0.8 mg/dL, 0.57:0.5 mg/dL in the GDM and control groups, respectively (p<0.05). There was no correlation between the OPN and hs-CRP levels (r=0.080; p=0.442). In GDM the patients are experiencing rapid metabolic changes, so these metabolic changes may not affect the level of OPN.

Özet

Amaç: Osteopontin (OPN) son zamanlarda koroner arter hastalığının bir belirteci olarak düşünülmektedir. Bu çalışmada, insulin direncinin arttığı bir durum olan gestasyonel diabetes mellitus/u (GDM) hastalarda,OPN seviyelerini ve bunun sensitif CRP (hs--CRP) seviyeleri ile korelasyonunu incelemek istedik. Gereç ve Yöntem: Çalışmaya 54 GDM ve 40 sağlıklı hamile alındı. 24. Gebelik haftasında kan lipid düzeyleri, oral glukoz yükleme testi, OPN, HOMA-IR, hs-CRP düzeyleri için kan tahlilleri yapıldı. Serum OPN düzeyleri ELISA, hs-- CRP düzeyleri parçacık ilişkili turbidimetrik test ile ölçüldü. Bulgular: Her iki grubun gestasyonel haftası, yaş, VKI benzerdi (p 0.05). GDM grubunda açlık glukoz, OGTT te ve 2. saat kan glukoz, HbA1c, açlık insulin, HOMA--IR değerleri kontrol grubuna göre istatistiksel olarak anlamlı daha yüksek saptandı. Trigliserid seviyeleri dışında lipid profilerinde her iki grupta anlamlı fark saptanmadı. GDM grubunda kontrol grubuna göre trigliserid seviyeleri daha yüksek saptandı (p 0.05). GDM ve kontrol gruplarında hs--CRP seviyeleri sırasıyla O.94i0.8 mg/dL, O.57i0.5 mg/dL saptandı (p<0.05). OPN ve hs--CRP seviyelerinde anlamlı korelasyon saptanmadı (r=0.080,' p=0.442). Gestasyonel diyabette hastalar hızlı metabolik değişiklikler yaşadığı için metabolik değişiklikler OPN seviyesini etkilemeyebilir. Sonuç: GDM'Iu hastalarda OPN seviyelerinde anlamlı artış saptanmamıştır.

🔖

Cite This Article

SAKLAMAZ, A., AKYILDIZ, M., KASAP, E., CENGİZ, H. (2017). Gestasyonel diabetes mellitusta osteopontin seviyeleri artmaz. Ege Tıp Dergisi, Cilt: 56 - Sayı: 4, 173–177. https://ajindex.com/articles/190214

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jovanovic L, Pettitt DJ. Gestational diabetes mellitus. JAMA 2001;286(20):2516-8
  2. Dennedy MC, Dunne F. The maternal and fetal impacts of obesity and gestational diabetes on pregnancy outcome. Best Pract Res Clin Endocrinol Metab 2010;24(4):573-89
  3. Kaufmann RC, Schleyhahn FT, Huffman DG, Amankwah KS. Gestational diabetes diagnostic criteria: Long-term maternal follow-up. Am J Obstet Gynecol 1995;172 (2 Pt 1):621-5
  4. Akinci B, Celtik A, Genc S, et al. Evaluation of postpartum carbohydrate intolerance and cardiovascular risk factors in women with gestational diabetes. Gynecol Endocrinol 2011;27(5):361-7
  5. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19(4):972-8
  6. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995; 44(4):369-74
  7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12):836-43
  8. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. C-reactive protein and gestational diabetes: The central role of maternal obesity. J Clin Endocrinol Metab 2003;88(8):3507-12
  9. Scatena M, Liaw L, Giachelli CM. Osteopontin. A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27(11):2302-9
  10. Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab 2014;3(4):384-93
  11. Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2012;167(5):1924-8
  12. Wendelin-Saarenhovi M, Oikonen M, Loo BM, et al. Plasma osteopontin is not associated with vascular markers of subclinical atherosclerosis in a population of young adults without symptoms of cardiovascular disease. The cardiovascular risk in young finns study. Scand J Clin Lab Invest 2011;71(8):683-9
  13. Ahmad R, Al-Mass A, Al-Ghawas D, et al. Interaction of osteopontin with IL-18 in obese individuals: Implications for insulin resistance. PLoS One 2013;8(5):e63944
  14. Stenczer B, Rigo J, Prohaszka Z, et al. Plasma osteopontin concentrat